Year-end Sale % OFF 
Abstract
Complement is an important component of both the innate and adaptive immune response that contributes to host defense in a variety of mechanisms, including inflammation, phagocytosis and cell lysis. Complement proteins are produced by all cell types in the CNS, and the same effector functions that protect the host from pathogens can mediate inflammation and tissue destruction in CNS diseases, leading to neurological deficits or even death. In the last 10 years, the development of complement inhibitors and a variety of animal models for CNS diseases has revealed that targeted inhibition of complement offers significant therapeutic potential. This review discusses the subtleties of targeted complement inhibition in CNS disease as an emerging therapeutic strategy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
